# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-055065
Filing Date
2024-05-08
Accepted
2024-05-08 07:21:05
Documents
62
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | tngx-20240331.htm iXBRL | 10-Q | 1362822
2 | EX-31.1 | tngx-ex31_1.htm | EX-31.1 | 15904
3 | EX-31.2 | tngx-ex31_2.htm | EX-31.2 | 15837
4 | EX-32.1 | tngx-ex32_1.htm | EX-32.1 | 7819
5 | EX-32.2 | tngx-ex32_2.htm | EX-32.2 | 7810
| Complete submission text file | 0000950170-24-055065.txt |  | 6092770

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | tngx-20240331.xsd | EX-101.SCH | 895699
66 | EXTRACTED XBRL INSTANCE DOCUMENT | tngx-20240331_htm.xml | XML | 1037339

Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39485 | Film No.: 24924241
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)